OS Therapies Incorporated
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OSTX research report →
About the company
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
- CEO
- Paul A. Romness
- IPO
- 2024
- Employees
- 5
- HQ
- Grasonville, MD, US
Price Chart
- Market Cap
- $84.18M
- P/E
- -1.77
- P/S
- 0.00
- P/B
- -6.75
- EV/EBITDA
- -2.44
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 2584.39%
- ROIC
- 407.60%
- Revenue
- $0 · 0.00%
- Net Income
- $-28,753,844 · -223.70%
- EPS
- $-0.98 · -88.46%
- Op Income
- $-28,705,701
- FCF YoY
- -195423.20%
- 52W High
- $2.57
- 52W Low
- $1.15
- 50D MA
- $1.78
- 200D MA
- $1.67
- Beta
- -0.83
- Avg Volume
- 782.78K
Get TickerSpark's AI analysis on OSTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 5, 24 | Romness Paul A. | other | 500,000 |
| Jan 22, 26 | McKean-Dieser Avril Suzette | other | 50,000 |
| Jan 22, 26 | Search Theodore F. | other | 50,000 |
| Jan 22, 26 | Ciccio John | other | 50,000 |
| Jan 22, 26 | Acevedo Christopher P. | other | 100,000 |
| Jan 22, 26 | PETIT ROBERT | other | 100,000 |
| Jan 22, 26 | Romness Paul A. | other | 1,000,000 |
| Jan 22, 26 | Jarry Olivier Roger | other | 50,000 |
| Jan 22, 26 | Galzahr Karim | other | 50,000 |
| Oct 21, 25 | Romness Paul A. | other | 1,000,000 |
Our OSTX coverage
Recent articles, reports, and earnings notes.
No research on OSTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OSTX report →Similar companies
Peers in the same neighborhood.